BCL2 Inhibitors: What’s the Latest Research?
BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia … Read more